Current small cell lung cancer treatment in China-Reference-Cited by-同舟云学术

Current small cell lung cancer treatment in China

Published:2015-01-15 Issue:3 Volume:6 Page:233-238
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Shi Yuankai¹²³,Xing Puyuan¹²³,Fan Yun⁴,Zhang Xin⁵,Hu Chengping⁶,Wang Caixia⁷,Liu Xiaoqing⁸,Chen Xiaoxia⁹,Zhou Jianying¹⁰,Wang Mengzhao¹¹,Wu Meina¹²,Han Baohui¹³,Fan Min¹⁴

Affiliation:

1. Department of Medical Oncology; Cancer Institute/ Hospital; Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC); Beijing China

2. National Center for Anticancer Drugs Clinical Study; Beijing China

3. Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; Beijing China

4. Department of Chemotherapy; Zhejiang Provincial Cancer Hospital; Hangzhou China

5. Department of Pulmonary Medicine; Zhongshan Hospital; Fudan University; Shanghai China

6. Department of Respiratory; Xiangya Hospital; Central South University; Changsha China

7. Department of Chemotherapy; Provincial Hospital affiliated to Shan dong University; Jinan China

8. Lung Tumor Department; Cancer Center; 307 Hospital of The PLA; Beijing China

9. Department of Medical Oncology; Shanghai Pulmonary Hospital; Tongji University School of Medicine; Tongji University Medical School Cancer Institute; Tongji University; Shanghai China

10. Department of Respiratory Disease, Thoracic Disease Center; The First Affiliated Hospital; College of Medicine; Zhejiang University; Hangzhou China

11. Department of Respiratory Medicine; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC); Beijing China

12. Thoracic Medical Oncology Department; Beijing Cancer Hospital & Institute; the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education); Peking University Cancer Hospital; Beijing China

13. Department of Pulmonary Medicine; Shanghai Chest Hospital; Shanghai Jiaotong University; Shanghai China

14. Department of Radiation Oncology; Shanghai Cancer Center; Fudan University; Shanghai China

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12218/fullpdf

Reference12 articles.

1. International Agency for Research on Cancer Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr

2. Annual report on status of cancer in China, 2010;Chen;Chin J Cancer Res,2014

3. Small-cell lung cancer;Jackman;Lancet,2005

4. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: small cell lung cancer. Version 1 2015 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl

5. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Früh;Ann Oncol,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine for the Treatment of Advanced NSCLC: Cimavax-EGF;Advances in Clinical Medicine;2023

2. Forced Overexpression of Signal Transducer and Activator of Transcription 3 (STAT3) Activates Yes-Associated Protein (YAP) Expression and Increases the Invasion and Proliferation Abilities of Small Cell Lung Cancer (SCLC) Cells;Biomedicines;2022-07-14

3. Lambert-Eaton Myasthenic Syndrome in Lung Cancer;Contrast Media & Molecular Imaging;2022-07-05

4. Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial;Cancer Medicine;2021-12-23

5. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial;Translational Lung Cancer Research;2021-09